<DOC>
	<DOCNO>NCT00641836</DOCNO>
	<brief_summary>Recent research indicate impairment vascular endothelial homeostasis play major role initiation development IPAH.We recently report safety feasibility data autologous endothelial progenitor cell ( EPCs ) injection patient IPAH . Yet many question remain unanswered : ideal quantity EPCs therapy , duration therapeutic effect , moreover , potential toxicity therapy . To help answer question , design one year follow-up investigate safety efficacy autologous EPCs injection patient IPAH .</brief_summary>
	<brief_title>Safety Feasibility Autologous Endothelial Progenitor Cells Transplantation Patients With Idiopathic Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>The inclusion criterion include baseline six minute walk distance 100 450 A rest mean pulmonaryartery pressure great 30 mm Hg A pulmonarycapillary wedge pressure le 15 mm Hg Pulmonary vascular resistance great 240 dyn•sec•cm5 1860 year old The exclusion criterion include secondary pulmonary hypertension result heart disease Pulmonary disease Sleepassociated disorder Chronic thromboembolic disease Autoimmune collagen vascular disease HIV infection Liver disease New York Heart Association functional class IV Major bleed require blood transfusion Diabetes Renal dysfunction Evidence malignant disease exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>